Explore the vast range of titles available.

Musculoskeletal models represent a powerful tool to gain knowledge on the internal forces acting at the joint level in a non-invasive way. However, these models can present some errors associated with the level of detail in their geometrical representation. For this reason, a thorough validation is necessary to prove the reliability of their predictions. This study documents the development of a generic musculoskeletal model and proposes a working logic and simulation techniques for identifying specific model features in need of refinement; as well as providing a quantitative validation for the prediction of hip contact forces (HCF). The model, implemented in the AnyBody Modeling System and based on the cadaveric dataset TLEM 2.0, was scaled to match the anthropometry of a patient fitted with an instrumented hip implant and to reproduce gait kinematics based on motion capture data. The relative contribution of individual muscle elements to the HCF and joint moments was analyzed to identify critical geometries, which were then compared to muscle magnetic resonance imaging (MRI) scans and, in case of inconsistencies, were modified to better match the volumetric scans. The predicted HCF showed good agreement with the overall trend and timing of the measured HCF from the instrumented prosthesis. The average root mean square error (RMSE), calculated for the total HCF was found to be 0.298*BW. Refining the geometries of the muscles thus identified reduced RMSE on HCF magnitudes by 17% (from 0.359*BW to 0.298*BW) over the whole gait cycle. The detailed study of individual muscle contributions to the HCF succeeded in identifying muscles with incorrect anatomy, which would have been difficult to intuitively identify otherwise. Despite a certain residual over-prediction of the final hip contact forces in the stance phase, a satisfactory level of geometrical accuracy of muscle paths has been achieved with the refinement of this model.

Preferred walking speed (PWS) is lower when wearing a controlled ankle motion (CAM) boot, which can potentially make comparisons between footwear conditions difficult. Standardising walking speed accounts for this but lacks the ecological validity of PWS. The aim of this study was to compare acute biomechanical responses to CAM boot wear when walking is freely chosen and when it is controlled. Twelve healthy participants walked on an instrumented treadmill at their PWS and at three standardised speeds: 3, 4, and 5 km/h. They did so in three footwear conditions: (1) with a Rebound® Air Walker CAM boot on the right leg, (2) with a Rebound® Air Walker on the right leg and an Evenup Shoelift[TM] on the left, and (3) in normal footwear. Comparisons between footwear conditions were largely similar in the ipsilateral limb at PWS and at the standardised speeds, which included a decrease in total mechanical work and ankle joint work during CAM boot wear (p < 0.001). At the standardised speeds, total mechanical work and hip joint work were lower during CAM boot wear than wearing normal shoes and the Evenup Shoelift[TM] (p [less than or equal to] 0.014), although there were no differences between footwear conditions at PWS (p [greater than or equal to] 0.095). As such, acute responses to CAM boot wear are different when speed is standardised compared to when speed is freely chosen, meaning conclusions cannot necessarily be transferred between approaches. Based on these differences observed between walking speeds, it would be prudent for future studies to try to maintain ecological validity by using PWS.

Preferred walking speed (PWS) is lower when wearing a controlled ankle motion (CAM) boot, which can potentially make comparisons between footwear conditions difficult. Standardising walking speed accounts for this but lacks the ecological validity of PWS. The aim of this study was to compare acute biomechanical responses to CAM boot wear when walking is freely chosen and when it is controlled. Twelve healthy participants walked on an instrumented treadmill at their PWS and at three standardised speeds: 3, 4, and 5 km/h. They did so in three footwear conditions: (1) with a Rebound® Air Walker CAM boot on the right leg, (2) with a Rebound® Air Walker on the right leg and an Evenup Shoelift™ on the left, and (3) in normal footwear. Comparisons between footwear conditions were largely similar in the ipsilateral limb at PWS and at the standardised speeds, which included a decrease in total mechanical work and ankle joint work during CAM boot wear ( p < 0.001). At the standardised speeds, total mechanical work and hip joint work were lower during CAM boot wear than wearing normal shoes and the Evenup Shoelift™ ( p ≤ 0.014), although there were no differences between footwear conditions at PWS ( p ≥ 0.095). As such, acute responses to CAM boot wear are different when speed is standardised compared to when speed is freely chosen, meaning conclusions cannot necessarily be transferred between approaches. Based on these differences observed between walking speeds, it would be prudent for future studies to try to maintain ecological validity by using PWS.

The capability to graft synthetic polymers onto the surfaces of live cells offers the potential to manipulate and control their phenotype and underlying cellular processes. Conventional grafting-to strategies for conjugating preformed polymers to cell surfaces are limited by low polymer grafting efficiency. Here we report an alternative grafting-from strategy for directly engineering the surfaces of live yeast and mammalian cells through cell surface-initiated controlled radical polymerization. By developing cytocompatible PET-RAFT (photoinduced electron transfer-reversible addition-fragmentation chain-transfer polymerization), synthetic polymers with narrow polydispersity ( M w / M n  < 1.3) could be obtained at room temperature in 5 minutes. This polymerization strategy enables chain growth to be initiated directly from chain-transfer agents anchored on the surface of live cells using either covalent attachment or non-covalent insertion, while maintaining high cell viability. Compared with conventional grafting-to approaches, these methods significantly improve the efficiency of grafting polymer chains and enable the active manipulation of cellular phenotypes. A cytocompatible controlled radical polymerization method has now been developed that initiates polymer synthesis directly on the surface of living cells. This method achieves significantly enhanced polymer grafting and enables active manipulation of cellular phenotypes.

Emerging strategies based on the self-assembly of block copolymers have recently enabled the bottom-up fabrication of nanostructured materials with spatially distinct functional regions. Concurrently, a drive for further miniaturization in applications such as optics, electronics and diagnostic technology has led to intense interest in nanomaterials with well-defined patterns of emission colour. Using a series of fluorescent block copolymers and the crystallization-driven living self-assembly approach, we herein describe the synthesis of multicompartment micelles in which the emission of each segment can be controlled to produce colours throughout the visible spectrum. This represents a bottom-up synthetic route to objects analogous to nanoscale pixels, into which complex patterns may be written. Because of their small size and high density of encoded information, these findings could lead to the development of new materials for applications in, for example, biological diagnostics, miniaturized display technology and the preparation of encoded nanomaterials with high data density. Controlling the colour and pattern of emission in nanoscale objects is still a challenging goal. Here the authors report segmented micelles where the emission from each individual section can be precisely controlled, giving nanomaterials capable of producing colours throughout the visible range.

Responsive hydrogels that undergo controlled shape changes in response to a range of stimuli are of interest for microscale soft robotic and biomedical devices. However, these applications require fabrication methods capable of preparing complex, heterogeneous materials. Here we report a new approach for making patterned, multi-material and multi-responsive hydrogels, on a micrometre to millimetre scale. Nanolitre aqueous pre-gel droplets were connected through lipid bilayers in predetermined architectures and photopolymerized to yield continuous hydrogel structures. By using this droplet network technology to pattern domains containing temperature-responsive or non-responsive hydrogels, structures that undergo reversible curling were produced. Through patterning of gold nanoparticle-containing domains into the hydrogels, light-activated shape change was achieved, while domains bearing magnetic particles allowed movement of the structures in a magnetic field. To highlight our technique, we generated a multi-responsive hydrogel that, at one temperature, could be moved through a constriction under a magnetic field and, at a second temperature, could grip and transport a cargo.Responsive hydrogels are of interest for a range of potential applications, including microscale soft robotic and biomedical devices. Now, a versatile fabrication approach has been developed to prepare patterned, multi-material and multi-responsive hydrogels. Pre-gel droplets are connected through lipid bilayers in predetermined architectures and photopolymerized to yield continuous hydrogel structures that respond to a variety of stimuli.

Equine herpesvirus‐1 (EHV‐1) is a highly prevalent and frequently pathogenic infection of equids. The most serious clinical consequences of infection are abortion and equine herpesvirus myeloencephalopathy (EHM). The previous consensus statement was published in 2009 and considered pathogenesis, strain variation, epidemiology, diagnostic testing, vaccination, outbreak prevention and control, and treatment. A recent survey of American College of Veterinary Internal Medicine large animal diplomates identified the need for a revision to this original consensus statement. This updated consensus statement is underpinned by 4 systematic reviews that addressed key questions concerning vaccination, pharmaceutical treatment, pathogenesis, and diagnostic testing. Evidence for successful vaccination against, or effective treatment of EHV‐1 infection was limited, and improvements in experimental design and reporting of results are needed in future studies of this important disease. This consensus statement also updates the topics considered previously in 2009.

Background Equine herpes virus type 1 (EHV‐1) infection in horses is associated with respiratory and neurologic disease, abortion, and neonatal death. Hypothesis Vaccines decrease the occurrence of clinical disease in EHV‐1‐infected horses. Methods A systematic review was performed searching multiple databases to identify relevant studies. Selection criteria were original peer‐reviewed research reports that investigated the in vivo use of vaccines for the prevention of disease caused by EHV‐1 in domesticated horses. Main outcomes of interest included pyrexia, abortion, neurologic disease, viremia, and nasal shedding. We evaluated risk of bias, conducted exploratory meta‐analyses of incidence data for the main outcomes, and performed a GRADE evaluation of the quality of evidence for each vaccine subtype. Results A total of 1018 unique studies were identified, of which 35 met the inclusion criteria. Experimental studies accounted for 31/35 studies, with the remainder being observational studies. Eight vaccine subclasses were identified including commercial (modified‐live, inactivated, mixed) and experimental (modified‐live, inactivated, deletion mutant, DNA, recombinant). Risk of bias was generally moderate, often because of underreporting of research methods, and sample sizes were small leading to imprecision in the estimate of the effect size. Several studies reported either no benefit or minimal vaccine efficacy for the primary outcomes of interest. Meta‐analyses revealed significant heterogeneity was present, and our confidence in the quality of evidence for most outcomes was low to moderate. Conclusions and Clinical Importance Our review indicates that commercial and experimental vaccines minimally reduce the incidence of clinical disease associated with EHV‐1 infection.

Background Equine herpes virus type 1 (EHV‐1) infection in horses is associated with upper respiratory disease, neurological disease, abortions, and neonatal death. Objective To determine if there is an association between the level and duration of EHV‐1 viremia and either abortion or equine herpesvirus myeloencephalopathy (EHM) in domesticated horses? Methods A systematic review was performed searching numerous databases to identify peer reviewed reports that evaluated viremia and EHM, or viremia and abortion published before January 19, 2021. Randomized controlled trials and observational studies were assessed for risk of bias or publication quality. Results A total of 189 unique studies were identified, of which 34 met the inclusion criteria. Thirty studies evaluated viremia and neurologic outcomes including 4 observational studies. Eight experimental studies examined viremia and abortion, which used the Ab4 and OH03 virus strains or recombinant Ab4 derivatives. Incidence rates for both EHM and abortion in experimental studies varied among the studies as did the level of evidence. Viremia was generally detectable before the onset of either EHM or abortion. Risk of bias was generally low to moderate, sample sizes were small, and multiple studies reported negative outcome data. Conclusions and Clinical Importance The results of this study support that viremia is regularly present before EHM or abortion occurs. However, no inferences could be made about the relationship between the occurrence of either neurological signs or abortion and the magnitude or duration of viremia.

Background Equine herpes virus type 1 (EHV‐1) infection in horses is associated with upper respiratory disease, neurological disease, abortions, and neonatal death. Review Question Does pharmacological therapy decrease either the incidence or severity of disease or infection caused by EHV‐1 in domesticated horses? Methods A systematic review was preformed searching AGRICOLA, CAB s, Cochrane, PubMed, Web of Science, and WHO Global Health Index Medicus Regional Databases to identify articles published before February 15, 2021. Selection criteria were original research reports published in peer reviewed journals, and studies investigating in vivo use of therapeutic agents for prevention or treatment of EHV‐1 in horses. Outcomes assessed included measures related to clinical outcomes that reflect symptomatic EHV‐1 infection or virus infection. We evaluated risk of bias and performed a GRADE evaluation of the quality of evidence for interventions. Results A total of 7009 unique studies were identified, of which 9 met the inclusion criteria. Two studies evaluated valacyclovir or small interfering RNAs, and single studies evaluated the use of a Parapoxvirus ovis‐based immunomodulator, human alpha interferon, an herbal supplement, a cytosine analog, and heparin. The level of evidence ranged between randomized controlled studies and observational trials. The risk of bias was moderate to high and sample sizes were small. Most studies reported either no benefit or minimal efficacy of the intervention tested. Conclusions and Clinical Importance Our review indicates minimal or limited benefit either as a prophylactic or post‐exposure treatment for any of the studied interventions in the mitigation of EHV‐1‐associated disease outcome.